Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

被引：0
|
作者：
Schjesvold, Fredrik H. [1 ,2 ]
Ludwig, Heinz [3 ]
Delimpasi, Sossana [4 ,5 ]
Robak, Pawel [6 ]
Coriu, Daniel [7 ]
Tomczak, Waldemar [8 ,9 ]
Pour, Ludek
Spicka, Ivan
Dimopoulos, Meletios-Athanasios [10 ]
Masszi, Tamas [11 ]
Chernova, Natalia G. [12 ]
Sandberg, Anna [13 ]
Thuresson, Marcus [13 ]
Norin, Stefan [13 ]
Bakker, Nicolaas A. [13 ]
Mateos, Maria-Victoria [14 ]
Richardson, Paul G. [15 ]
Sonneveld, Pieter [16 ]
机构：
[1] Univ Oslo, Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway
[2] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway
[3] Wilhelminen Canc Res Inst, Ctr Med Oncol & Hematol, Dept Med 1, Outpatient Dept & Palliat Care, Vienna, Austria
[4] Evangelismos Med Ctr, Bone Marrow Transplantat Unit, Athens, Greece
[5] Evangelismos Med Ctr, Dept Hematol, Athens, Greece
[6] Univ Hosp Ostrava, Dept Hemato Oncol, Ostrava, Czech Republic
[7] Univ Med & Pharm Carol Davila, Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania
[8] Med Univ Lublin, Dept HematoOncol, Lublin, Poland
[9] Med Univ Lublin, Bone Marrow Transplantat, Lublin, Poland
[10] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece
[11] Semmelwe Univ, Dept Internal Med & Hematol, Budapest, Hungary
[12] Natl Res Ctr Hematol, Moscow, Russia
[13] Oncopeptides AB, Stockholm, Sweden
[14] Hosp Clin Univ Salamanca, IBSAL, CIC, Salamanca, Spain
[15] Dana Farber Canc Inst, USA, Boston, MA USA
[16] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2331 / 2336
页数：6
相关论文
共 50 条
  • [31] COMPARISON OF PATIENTS' AND PHYSICIANS' PERCEPTIONS OF PATIENTS' BASELINE HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Broek, I.
    Murphy, P.
    Petrucci, M.
    Kyriakou, C.
    Welslau, M.
    Bacon, P.
    Lewis, P.
    Gilet, H.
    Arnould, B.
    Bottomley, A.
    Leleu, X.
    [J]. HAEMATOLOGICA, 2013, 98 : 443 - 443
  • [32] LONGITUDINAL COMPARISON OF PATIENTS' AND PHYSICIANS' PERCEPTIONS OF PATIENTS' HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Vande Broek, I.
    Petrucci, M. T.
    Leleu, X.
    Murphy, P.
    Welslau, M.
    Bacon, P.
    Lewis, P.
    Gilet, H.
    Arnould, B.
    Kyriakou, C.
    [J]. HAEMATOLOGICA, 2014, 99 : 368 - 368
  • [33] Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma
    Nitya Nathwani
    Jill Bell
    Dasha Cherepanov
    France Ginchereau Sowell
    Rachel Shah
    Kelly McCarrier
    Parameswaran Hari
    [J]. Supportive Care in Cancer, 2022, 30 : 5859 - 5869
  • [34] Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma
    Nathwani, Nitya
    Bell, Jill
    Cherepanov, Dasha
    Sowell, France Ginchereau
    Shah, Rachel
    McCarrier, Kelly
    Hari, Parameswaran
    [J]. SUPPORTIVE CARE IN CANCER, 2022, 30 (07) : 5859 - 5869
  • [35] EXPLORATION AND QUANTIFICATION OF THE DETERMINANTS OF BASELINE HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR PATIENTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Kyriakou, C.
    Petrucci, M.
    Welslau, M.
    Leleu, X.
    Vande Broek, I.
    Bacon, P.
    Lewis, P.
    Gilet, H.
    Arnould, B.
    Murphy, P.
    [J]. HAEMATOLOGICA, 2013, 98 : 600 - 600
  • [36] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
    Weisel, Katja
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Lord-Bessen, Jennifer
    Yip, Christine
    Greenwood, Mike
    Tang, Jackson
    Cavo, Michele
    [J]. HEMASPHERE, 2023, 7 (03): : E843
  • [37] ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
    Ocio, Enrique M.
    Efebera, Yvonne A.
    Hajek, Roman
    Straub, Jan
    Maisnar, Vladimir
    Eveillard, Jean-Richard
    Karlin, Lionel
    Mateos, Maria -Victoria
    Oriol, Albert
    Ribrag, Vincent
    Richardson, Paul G.
    Norin, Stefan
    Obermueller, Jakob
    Bakker, Nicolaas A.
    Pour, Ludek
    [J]. HAEMATOLOGICA, 2024, 109 (03) : 867 - 876
  • [38] Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated PatientReported Outcomes from the Phase 1/2 MonumenTAL-1 Study
    Schinke, Carolina
    Touzeau, Cyrille
    Oriol, Albert
    Mateos, Maria-Victoria
    Stevens, Don A.
    Rasche, Leo
    Qin, Xiang
    Kato, Kelly
    Ming, Timothy
    Katz, Eva G.
    Gries, Katharine S.
    Campagna, Michela
    Masterson, Tara J.
    Hilder, Brandi W.
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Moreau, Philippe
    San-Miguel, Jesus
    Rodriguez Otero, Paula
    Chari, Ajai
    [J]. BLOOD, 2023, 142
  • [39] Phase II study of thalidomide with dexamethasone for relapsed/refractory multiple myeloma
    Kinoshita, T
    Ohno, T
    Yuge, M
    Hiraga, J
    Matsushita, T
    Ando, S
    Naoe, T
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 206 - 206
  • [40] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial
    Weisel, Katja
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Lord-Bessen, Jennifer
    Yao, David
    Yip, Christine
    Greenwood, Mike
    Tang, Jackson
    Cavo, Michele
    [J]. BLOOD, 2021, 138
12345